| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ACBM Stock Overview
Acro Biomedical Co., Ltd. engages in developing and marketing of nutritional products.
Acro Biomedical Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.48 |
| 52 Week High | US$5.00 |
| 52 Week Low | US$2.03 |
| Beta | 1.16 |
| 1 Month Change | 11.72% |
| 3 Month Change | 12.00% |
| 1 Year Change | 5.41% |
| 3 Year Change | -10.40% |
| 5 Year Change | n/a |
| Change since IPO | 79.20% |
Recent News & Updates
Shareholder Returns
| ACBM | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 12.3% | 2.3% | 3.2% |
| 1Y | 5.4% | 14.7% | -10.2% |
Return vs Industry: ACBM underperformed the US Healthcare industry which returned 17.7% over the past year.
Return vs Market: ACBM exceeded the US Market which returned -10.1% over the past year.
Price Volatility
| ACBM volatility | |
|---|---|
| ACBM Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 8.8% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: Insufficient data to determine ACBM's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine ACBM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Richard Chu | https://acrobiomedicalco.com |
Acro Biomedical Co., Ltd. engages in developing and marketing of nutritional products. It sells cordycepin and cordyceps powder, a fungus used in traditional Chinese medicine. The company was formerly known as Killer Waves Hawaii, Inc. and changed its name to Acro Biomedical Co., Ltd.
Acro Biomedical Fundamentals Summary
| ACBM fundamental statistics | |
|---|---|
| Market Cap | US$268.99m |
| Earnings (TTM) | -US$14.77m |
| Revenue (TTM) | US$896.50k |
300.1x
P/S Ratio-18.2x
P/E RatioIs ACBM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACBM income statement (TTM) | |
|---|---|
| Revenue | US$896.50k |
| Cost of Revenue | US$670.00k |
| Gross Profit | US$226.50k |
| Other Expenses | US$15.00m |
| Earnings | -US$14.77m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 25.26% |
| Net Profit Margin | -1,647.42% |
| Debt/Equity Ratio | 3.7% |
How did ACBM perform over the long term?
See historical performance and comparisonValuation
Is ACBM undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ACBM?
Other financial metrics that can be useful for relative valuation.
| What is ACBM's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$268.99m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 300.1x |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does ACBM's PB Ratio compare to its peers?
| ACBM PB Ratio vs Peers |
|---|
| Company | PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 31.5x | ||
AATP Agape ATP | 119.8x | n/a | US$302.6m |
PETQ PetIQ | 1.6x | n/a | US$438.7m |
GEG Great Elm Group | 1.7x | n/a | US$59.9m |
OMI Owens & Minor | 2.8x | 21.2% | US$2.7b |
ACBM Acro Biomedical | 468.1x | n/a | US$269.0m |
Price-To-Book vs Peers: ACBM is expensive based on its Price-To-Book Ratio (468.1x) compared to the peer average (31.5x).
Price to Earnings Ratio vs Industry
How does ACBM's PE Ratio compare vs other companies in the US Healthcare Industry?
Price-To-Book vs Industry: ACBM is expensive based on its Price-To-Book Ratio (468.1x) compared to the US Healthcare industry average (2.7x)
Price to Book Ratio vs Fair Ratio
What is ACBM's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 468.1x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate ACBM's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of ACBM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ACBM's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ACBM's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Future Growth
How is Acro Biomedical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
12.9%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Acro Biomedical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine Acro Biomedical's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Acro Biomedical's filings and announcements here.
Past Performance
How has Acro Biomedical performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-92.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ACBM is currently unprofitable.
Growing Profit Margin: ACBM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ACBM is unprofitable, and losses have increased over the past 5 years at a rate of 92.4% per year.
Accelerating Growth: Unable to compare ACBM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACBM is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (8.1%).
Return on Equity
High ROE: ACBM has a negative Return on Equity (-2569.04%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Acro Biomedical's financial position?
Financial Health Score
4/6Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ACBM's short term assets ($626.9K) exceed its short term liabilities ($81.5K).
Long Term Liabilities: ACBM's short term assets ($626.9K) exceed its long term liabilities ($13.0K).
Debt to Equity History and Analysis
Debt Level: ACBM's net debt to equity ratio (1.6%) is considered satisfactory.
Reducing Debt: ACBM had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ACBM has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ACBM has less than a year of cash runway if free cash flow continues to grow at historical rates of 32.1% each year.
Discover healthy companies
Dividend
What is Acro Biomedical current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ACBM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ACBM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ACBM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ACBM's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ACBM has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
Richard Chu (68 yo)
5.58yrs
Tenure
Mr. Pao-Chi Chu, also known as Richard, has been Chief Executive Officer, President, Chief Financial Officer, Secretary and Director of Acro Biomedical Co., Ltd. since January 30, 2017 and serves as its Ch...
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.1%.
Top Shareholders
Company Information
Acro Biomedical Co., Ltd.'s employee growth, exchange listings and data sources
Key Information
- Name: Acro Biomedical Co., Ltd.
- Ticker: ACBM
- Exchange: OTCPK
- Founded: 2014
- Industry: Health Care Distributors
- Sector: Healthcare
- Implied Market Cap: US$268.988m
- Shares outstanding: 60.04m
- Website: https://acrobiomedicalco.com
Location
- Acro Biomedical Co., Ltd.
- 12175 Visionary Way
- Suite 1160
- Fishers
- Indiana
- 46038
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/13 00:00 |
| End of Day Share Price | 2022/08/11 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.